CymaBay Therapeutics, Inc. Contracts & Agreements
54 Contracts & Agreements
- Business Finance (17 contracts)
- Business Operations (4)
- Human Resources (11)
- Intellectual Property (4)
- Mergers & Acquisitions (1)
- Real Estate (4)
- Uncategorized (13)
- Agreement of Sublease, dated December 1, 2023, between CymaBay Therapeutics, Inc. and Meta Platforms, Inc (Filed With SEC on February 28, 2024)
- Form of RSU Award Grant Notice and RSU Award Agreement under the 2023 Equity Incentive Plan (Filed With SEC on February 28, 2024)
- Second Amendment to Lease, dated February 6, 2024, between CymaBay Therapeutics, Inc. and BMR-Pacific Research Center, LP (Filed With SEC on February 28, 2024)
- Agreement and Plan of Merger, dated as of February 11, 2024, by and among CymaBay Therapeutics, Inc., Gilead Sciences, Inc. and Pacific Merger Sub, Inc (Filed With SEC on February 12, 2024)
- Non-Employee Director Compensation Program (Filed With SEC on January 26, 2024)
- Underwriting Agreement, dated September 11, 2023 (Filed With SEC on September 12, 2023)
- Form of Pre-Funded Warrant (Filed With SEC on September 12, 2023)
- CymaBay Therapeutics, Inc. 2020 New Hire Plan (Filed With SEC on August 10, 2023)
- Offer Letter, dated April 27, 2023, between CymaBay Therapeutics, Inc. and Harish Shantharam (Filed With SEC on May 9, 2023)
- Collaboration and License Agreement, dated January 6, 2023, between CymaBay Therapeutics, Inc. and Kaken Pharmaceutical Co., Ltd (Filed With SEC on March 23, 2023)
- Notice of Resignation and Transition Agreement, effective February 20, 2023, between CymaBay Therapeutics, Inc. and Dennis Kim (Filed With SEC on February 23, 2023)
- Underwriting Agreement, dated January 23, 2023 (Filed With SEC on January 25, 2023)
- Form of Pre-Funded Warrant (Filed With SEC on January 25, 2023)
- PPARd License Agreement, dated June 20, 2006, by and between Metabolex, Inc. and Janssen Pharmaceutica NV (Filed With SEC on November 14, 2022)
- Underwriting Agreement, dated November 17, 2021 (Filed With SEC on November 18, 2021)
- Form of Pre-Funded Warrant (Filed With SEC on November 18, 2021)
- Development Financing Agreement, dated July 30, 2021, by and between CymaBay Therapeutics, Inc. and ABW Cyclops SPV LP (Filed With SEC on November 10, 2021)
- Offer letter, dated April 30, 2021, between CymaBay Therapeutics, Inc. and Dennis D. Kim (Filed With SEC on August 12, 2021)
- Offer letter, dated March 24, 2021, between CymaBay Therapeutics, Inc. and Lewis Stuart (Filed With SEC on August 12, 2021)
- Offer Letter, dated August 27, 2020, between CymaBay Therapeutics, Inc. and Paul Quinlan (Filed With SEC on March 25, 2021)
- Form of Stock Option Grant Notice and Option Agreement under the 2020 New Hire Plan (Filed With SEC on March 25, 2021)
- 2020 New Hire Plan (Filed With SEC on March 25, 2021)
- Description of Common Stock (Filed With SEC on March 25, 2021)
- Description of Common Stock (Filed With SEC on March 16, 2020)
- Offer letter, dated June 18, 2019, between CymaBay Therapeutics, Inc. and Janet Dorling (Filed With SEC on August 7, 2019)
- Underwriting Agreement, dated March 5, 2019 (Filed With SEC on March 6, 2019)
- Non-Employee Director Compensation Program (Filed With SEC on February 28, 2019)
- Offer Letter, dated September 4, 2018, between CymaBay Therapeutics, Inc. and Klara Dickinson (Filed With SEC on February 28, 2019)
- Amended Offer Letter, dated September 4, 2018, by and between CymaBay Therapeutics, Inc. and Paul Quinlan (Filed With SEC on November 6, 2018)
- CymaBay Therapeutics, Inc. amended and restated 2013 Equity Incentive Plan (Filed With SEC on June 7, 2018)
- First Amendment to Lease, dated April 16, 2018, between BMR-Pacific Research Center LP and CymaBay Therapeutics, Inc (Filed With SEC on May 8, 2018)
- Form of CymaBay Indemnity Agreement (Filed With SEC on March 15, 2018)
- Offer Letter, dated November 9, 2017, between CymaBay Therapeutics, Inc. and Paul Quinlan (Filed With SEC on March 15, 2018)
- Non-Employee Director Compensation Program (Filed With SEC on March 15, 2018)
- Underwriting Agreement, dated January 29, 2018 (Filed With SEC on January 30, 2018)
- PPAR-d License Agreement, dated June 30, 2006, by and between CymaBay Therapeutics, Inc. (formerly Metabolex, Inc.) and Janssen Pharmaceutical NV (Filed With SEC on January 12, 2018)
- EXHIBIT A Employee Confidential Information and Inventions Assignments Agreement (Filed With SEC on August 10, 2017)
- 13,000,000 Shares CYMABAY THERAPEUTICS, INC. Common Stock UNDERWRITING AGREEMENT (Filed With SEC on July 19, 2017)
- Exclusive License Agreement between CymaBay Therapeutics,Inc. (as the licensor) and Kowa PharmaceuticalsAmerica, Inc. (as the licensee) dated as of December 30, 2016 TABLE OF... (Filed With SEC on March 23, 2017)
- SECOND AMENDMENT (Filed With SEC on March 23, 2017)
- CymaBay Therapeutics, Inc. Amended and Restated Non-Employee Directors Compensation Program (Filed With SEC on March 23, 2017)
- 5,181,348 Shares CYMABAY THERAPEUTICS, INC. Common Stock UNDERWRITING AGREEMENT (Filed With SEC on February 3, 2017)
- MASTERSERVICES AGREEMENT FOR CLINICAL PHASE IIb/III DEVELOPMENT SERVICES ONLY (Filed With SEC on November 12, 2015)
- LOAN AND SECURITY AGREEMENT (Filed With SEC on November 12, 2015)
- 7,120,000 Shares CYMABAY THERAPEUTICS, INC. Common Stock UNDERWRITING AGREEMENT (Filed With SEC on July 15, 2015)
- CymaBay Therapeutics, Inc. Amended and Restated Non-Employee Directors Compensation Program (Filed With SEC on March 23, 2015)
- PPAR-d LICENSE AGREEMENT (Filed With SEC on November 14, 2014)
- CYMABAY THERAPEUTICS, INC. 2013 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS:SEPTEMBER 25, 2013 APPROVED BY THE STOCKHOLDERS:SEPTEMBER 30, 2013 EFFECTIVE DATE:... (Filed With SEC on June 6, 2014)
- Non-Employee Director Compensation Policy (Filed With SEC on April 8, 2014)
- MASTER SERVICES AGREEMENT (Filed With SEC on April 8, 2014)
- [] Shares CYMABAY THERAPEUTICS, INC. Common Stock UNDERWRITING AGREEMENT (Filed With SEC on April 8, 2014)
- CYMABAY THERAPEUTICS, INC. INCENTIVE AWARD GRANT NOTICE (2013 EQUITY PLAN) (Filed With SEC on March 31, 2014)
- CYMABAY THERAPEUTICS, INC. AMENDMENT NO. 1 TO REGISTRATION RIGHTS AGREEMENT (Filed With SEC on March 31, 2014)
- LEASE by and between BMR-PACIFIC RESEARCH CENTER LP, aDelaware limited partnership and CYMABAY THERAPEUTICS, INC., aDelaware corporation (Filed With SEC on November 25, 2013)
